Williams ME - Search Results

1

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.

Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Beum PV, et al. Among authors: williams me. J Immunol Methods. 2004 Nov;294(1-2):37-42. doi: 10.1016/j.jim.2004.08.004. J Immunol Methods. 2004. PMID: 15604014

2

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Kennedy AD, et al. Among authors: williams me. J Immunol. 2004 Mar 1;172(5):3280-8. doi: 10.4049/jimmunol.172.5.3280. J Immunol. 2004. PMID: 14978136

3

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. Beum PV, et al. Among authors: williams me. J Immunol. 2006 Feb 15;176(4):2600-9. doi: 10.4049/jimmunol.176.4.2600. J Immunol. 2006. PMID: 16456022

4

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, Taylor RP. Williams ME, et al. J Immunol. 2006 Nov 15;177(10):7435-43. doi: 10.4049/jimmunol.177.10.7435. J Immunol. 2006. PMID: 17082663

5

Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.

Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Li Y, et al. Among authors: williams me. J Immunol. 2007 Sep 15;179(6):4263-71. doi: 10.4049/jimmunol.179.6.4263. J Immunol. 2007. PMID: 17785867

6

New therapies for mantle cell lyphoma.

Williams ME. Williams ME. Clin Adv Hematol Oncol. 2003 Dec;1(12):708, 11. Clin Adv Hematol Oncol. 2003. PMID: 16258472 No abstract available.

7

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma.

Prichard M, Harris T, Williams ME, Densmore JJ. Prichard M, et al. Among authors: williams me. Expert Opin Pharmacother. 2009 Apr;10(6):983-95. doi: 10.1517/14656560902895715. Expert Opin Pharmacother. 2009. PMID: 19364248 Review.

8

Transplantation for mantle cell lymphoma: is it the right thing to do?

Williams ME. Williams ME. Hematology Am Soc Hematol Educ Program. 2013;2013:568-74. doi: 10.1182/asheducation-2013.1.568. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319233 Review.

9

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Kahl BS, et al. Among authors: williams me. J Clin Oncol. 2014 Oct 1;32(28):3096-102. doi: 10.1200/JCO.2014.56.5853. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154829 Free PMC article. Clinical Trial.

10

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Wagner LI, et al. Among authors: williams me. J Clin Oncol. 2015 Mar 1;33(7):740-8. doi: 10.1200/JCO.2014.57.6801. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605841 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

552 results

Search Page